| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.15 | 0.01 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.01 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |